N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma

AbstractBackground. Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alk

Saved in:

Bibliographic Details
Main Authors:	Wick, Wolfgang (Author) , Dettmer, Susan (Author) , Berberich, Anne (Author) , Keßler, Tobias (Author) , Karapanagiotou-Schenkel, Irini (Author) , Wick, Antje (Author) , Winkler, Frank (Author) , Pfaff, Elke (Author) , Brors, Benedikt (Author) , Debus, Jürgen (Author) , Unterberg, Andreas (Author) , Bendszus, Martin (Author) , Herold-Mende, Christel (Author) , Eisenmenger, Andreas (Author) , Deimling, Andreas von (Author) , Jones, David T. W. (Author) , Pfister, Stefan (Author) , Sahm, Felix (Author) , Platten, Michael (Author)
Format:	Article (Journal)
Language:	English
Published:	[January 2019]
In:	Neuro-Oncology Year: 2018, Volume: 21, Issue: 1, Pages: 95-105
ISSN:	1523-5866
DOI:	10.1093/neuonc/noy161
Online Access:	Verlag, Volltext: https://doi.org/10.1093/neuonc/noy161 Verlag, Volltext: https://academic.oup.com/neuro-oncology/article/21/1/95/5113425
Author Notes:	Wolfgang Wick, Susan Dettmer, Anne Berberich, Tobias Kessler, Irini Karapanagiotou-Schenkel, Antje Wick, Frank Winkler, Elke Pfaff, Benedikt Brors, Jürgen Debus, Andreas Unterberg, Martin Bendszus, Christel Herold-Mende, Andreas Eisenmenger, Andreas von Deimling, David T.W. Jones, Stefan M. Pfister, Felix Sahm, and Michael Platten

Description
Summary:	AbstractBackground. Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alk
Item Description:	Published: 01 October 2018 Im Titel ist die Ziffer 2 hochgestellt Gesehen am 26.06.2019
Physical Description:	Online Resource
ISSN:	1523-5866
DOI:	10.1093/neuonc/noy161